Scarica l'app Stockscreener
4.49
2.51%
0.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HUMA Giù?
Forum
Previsione
Humacyte Inc Borsa (HUMA) Ultime notizie
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Humacyte, Inc. Shareholder Alert: Robbins LLP Reminds Investors of the HUMA Securities Class Action - GlobeNewswire
Humacyte, Inc. Shareholder Alert: Robbins LLP Reminds Investors of the HUMA Securities Class Action - GlobeNewswire Inc.
HUMA DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before January 17, 2025 - The Globe and Mail
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead - The Bakersfield Californian
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 – HUMA - Morningstar
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH) - The Manila Times
Humacyte sees success in dual emergency-engineered tissue trials - Yahoo Finance
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders - Marketscreener.com
HUMA Deadline to Lead in Securities Fraud Lawsuit is January 17, 2025Contact Kaplan Fox & Kilsheimer LLP - The Globe and Mail
HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Morningstar
Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues – Hagens Berman - GlobeNewswire
Humacyte director Brady Dougan buys $7,978 in common stock - Investing.com India
ROSEN, LEADING INVESTOR COUNSEL, Encourages Humacyte, Inc. - GlobeNewswire
HUMACYTE, INC. (NASDAQ: HUMA) INVESTOR ALERT: Investors - GlobeNewswire
Insider Buyers At Humacyte Likely Disappointed With 17% Slide - Yahoo Finance
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
HUMA INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $00,000 In HUMA To Contact Him Directly To Discuss Their Options - PR Newswire
Humacyte announces publication of results on ATEV - TipRanks
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery - The Manila Times
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial - EIN News
Humacyte CEO Laura Niklason buys shares worth $7,978 - Investing.com
Humacyte CEO Laura Niklason buys shares worth $7,978 By Investing.com - Investing.com UK
Humacyte director Brady Dougan buys $7,978 in common stock By Investing.com - Investing.com UK
Humacyte CEO Laura Niklason sells $6.6m in common stock By Investing.com - Investing.com Nigeria
Humacyte CEO Laura Niklason sells $6.6m in common stock - Investing.com India
Humacyte director Brady Dougan sells shares worth $6.6 million By Investing.com - Investing.com Nigeria
Humacyte director Brady Dougan sells shares worth $6.6 million - Investing.com
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Humacyte, Inc. (HUMA) - EIN News
HUMA LAWSUIT ALERT: Levi & Korsinsky LLP Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - TipRanks
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Investors - Business Wire
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Blood Vessel Maker Faces Investor Suit Over FDA Findings - Law360
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Humacyte, Inc. - PR Newswire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Investors - Business Wire
Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights - The Bakersfield Californian
Humacyte Faces Financial Uncertainty: Potential Impact on Share Price and Capital - MSN
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Shareholder lawsuit shines light on biotech's FDA woes - The Business Journals
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues– Hagens Berman - GlobeNewswire
HUMA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Humacyte, Inc. - Business Wire
Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association's Scientific Sessions 2024 - The Manila Times
Humacyte, Inc. Presents Preclinical Results of Small-Diameter ATEV?? for Coronary Artery Bypass Grafting at American Heart Association's Scientific Sessions 2024 - Marketscreener.com
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - GlobeNewswire
Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
HC Wainwright Decreases Earnings Estimates for Humacyte - MarketBeat
Humacyte Advances with $15M Direct Offering - TipRanks
Cantor Fitzgerald Reduces Earnings Estimates for Humacyte - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Humacyte, Inc. (HUMA) Shareholders to Inquire about Securities Investigation - AccessWire
Humacyte Announces Pricing of $15.0 Million Registered Direct Offering - The Manila Times
Humacyte's (HUMA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Humacyte, Inc. (HUMA) And Encourages Shareholders to Reach Out - AccessWire
1.89%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):